{"title":"沙利度胺联合异环磷酰胺可显著提高肺转移性骨肉瘤患者的生存率。","authors":"Yuanxiang Liu, Huabin Wang, Zhengkai Xiang","doi":"10.62347/AEWT1662","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy and safety of thalidomide combined with ifosfamide (IFO) in the treatment of pulmonary metastatic osteosarcoma and to compare its outcomes with the IFO plus etoposide (ETOP) regimen, providing a reference for the clinical treatment of osteosarcoma.</p><p><strong>Methods: </strong>In this retrospective study, clinical data from 95 patients with pathologically confirmed osteosarcoma were analyzed. Of these, 55 patients received thalidomide + IFO (Observation group), and 40 patients received IFO + ETOP (Control group). Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse reactions (ARs) were compared between the two groups.</p><p><strong>Results: </strong>After treatment, the maximum diameters of both primary tumors and lung metastatic (LM) lesions in the Observation group were significantly smaller than those in the Control group. The median PFS was 10 months in the Observation group and 7.5 months in the Control group; the median OS was 22 months in the Observation group and 14 months in the Control group. The ORR and DCR in the Observation group were 23.63% and 52.73%, both significantly higher than those in the Control group (P<0.05). The incidences of hematological toxicity, gastrointestinal reactions, and renal dysfunction were significantly lower in the Observation group than in the Control group (<i>P</i><0.05). Multivariate Cox regression analysis identified number of pulmonary metastases (HR=1.256, <i>P</i>=0.038), T stage (HR=1.453, <i>P</i>=0.033), N stage (HR=1.389, <i>P</i>=0.035), receipt of radiotherapy (HR=1.589, <i>P</i>=0.018), and LDH levels (HR=1.356, <i>P</i>=0.015) as independent prognostic factors for pulmonary metastatic osteosarcoma.</p><p><strong>Conclusion: </strong>Thalidomide + IFO notably improves PFS and OS in patients with pulmonary metastatic osteosarcoma, demonstrating superior safety compared with the IFO-ETOP regimen.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 8","pages":"3795-3807"},"PeriodicalIF":2.9000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432580/pdf/","citationCount":"0","resultStr":"{\"title\":\"Thalidomide combined with ifosfamide significantly improves survival in patients with pulmonary metastatic osteosarcoma.\",\"authors\":\"Yuanxiang Liu, Huabin Wang, Zhengkai Xiang\",\"doi\":\"10.62347/AEWT1662\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate the efficacy and safety of thalidomide combined with ifosfamide (IFO) in the treatment of pulmonary metastatic osteosarcoma and to compare its outcomes with the IFO plus etoposide (ETOP) regimen, providing a reference for the clinical treatment of osteosarcoma.</p><p><strong>Methods: </strong>In this retrospective study, clinical data from 95 patients with pathologically confirmed osteosarcoma were analyzed. Of these, 55 patients received thalidomide + IFO (Observation group), and 40 patients received IFO + ETOP (Control group). Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse reactions (ARs) were compared between the two groups.</p><p><strong>Results: </strong>After treatment, the maximum diameters of both primary tumors and lung metastatic (LM) lesions in the Observation group were significantly smaller than those in the Control group. The median PFS was 10 months in the Observation group and 7.5 months in the Control group; the median OS was 22 months in the Observation group and 14 months in the Control group. The ORR and DCR in the Observation group were 23.63% and 52.73%, both significantly higher than those in the Control group (P<0.05). The incidences of hematological toxicity, gastrointestinal reactions, and renal dysfunction were significantly lower in the Observation group than in the Control group (<i>P</i><0.05). Multivariate Cox regression analysis identified number of pulmonary metastases (HR=1.256, <i>P</i>=0.038), T stage (HR=1.453, <i>P</i>=0.033), N stage (HR=1.389, <i>P</i>=0.035), receipt of radiotherapy (HR=1.589, <i>P</i>=0.018), and LDH levels (HR=1.356, <i>P</i>=0.015) as independent prognostic factors for pulmonary metastatic osteosarcoma.</p><p><strong>Conclusion: </strong>Thalidomide + IFO notably improves PFS and OS in patients with pulmonary metastatic osteosarcoma, demonstrating superior safety compared with the IFO-ETOP regimen.</p>\",\"PeriodicalId\":7437,\"journal\":{\"name\":\"American journal of cancer research\",\"volume\":\"15 8\",\"pages\":\"3795-3807\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432580/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.62347/AEWT1662\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/AEWT1662","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Thalidomide combined with ifosfamide significantly improves survival in patients with pulmonary metastatic osteosarcoma.
Objective: To evaluate the efficacy and safety of thalidomide combined with ifosfamide (IFO) in the treatment of pulmonary metastatic osteosarcoma and to compare its outcomes with the IFO plus etoposide (ETOP) regimen, providing a reference for the clinical treatment of osteosarcoma.
Methods: In this retrospective study, clinical data from 95 patients with pathologically confirmed osteosarcoma were analyzed. Of these, 55 patients received thalidomide + IFO (Observation group), and 40 patients received IFO + ETOP (Control group). Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse reactions (ARs) were compared between the two groups.
Results: After treatment, the maximum diameters of both primary tumors and lung metastatic (LM) lesions in the Observation group were significantly smaller than those in the Control group. The median PFS was 10 months in the Observation group and 7.5 months in the Control group; the median OS was 22 months in the Observation group and 14 months in the Control group. The ORR and DCR in the Observation group were 23.63% and 52.73%, both significantly higher than those in the Control group (P<0.05). The incidences of hematological toxicity, gastrointestinal reactions, and renal dysfunction were significantly lower in the Observation group than in the Control group (P<0.05). Multivariate Cox regression analysis identified number of pulmonary metastases (HR=1.256, P=0.038), T stage (HR=1.453, P=0.033), N stage (HR=1.389, P=0.035), receipt of radiotherapy (HR=1.589, P=0.018), and LDH levels (HR=1.356, P=0.015) as independent prognostic factors for pulmonary metastatic osteosarcoma.
Conclusion: Thalidomide + IFO notably improves PFS and OS in patients with pulmonary metastatic osteosarcoma, demonstrating superior safety compared with the IFO-ETOP regimen.
期刊介绍：
The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
